Replimune to Present New Biomarker & Pre-clinical Data for Lead Oncolytic Immunotherapy Programs at the 2021 American Association for Cancer Research Annual Meeting
12. April 2021 16:01 ET
|
Replimune Group Inc
Data confirms potent anti-tumor activity & activation of robust systemic immune responses by RP1 and RP2 Increased infiltration of CD8+ T cells and PD-L1 expression for patients dosed with RP1 in...
Replimune to Present at the American Association for Cancer Research Annual Meeting 2021
11. März 2021 16:01 ET
|
Replimune Group Inc
WOBURN, Mass., March 11, 2021 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today...
Replimune to Present at Three Upcoming Investor Conferences
04. März 2021 08:00 ET
|
Replimune Group Inc
WOBURN, Mass., March 04, 2021 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today...
Replimune to Present at the SVB Leerink 10th Annual Global Healthcare Conference
18. Februar 2021 08:00 ET
|
Replimune Group Inc
WOBURN, Mass., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today...
Replimune Reports Third Fiscal Quarter Financial Results and Provides Corporate Update
04. Februar 2021 08:00 ET
|
Replimune Group Inc
RP1: Initial data in new indications expected in 2021 in anti-PD1 failed NSCLC, anti-PD1 failed CSCC and CSCC solid organ transplant recipient patients; further updates expected to be provided across...
Replimune Provides 2020 Year End Review and Overview of Expected 2021 Milestones
11. Januar 2021 07:00 ET
|
Replimune Group Inc
RP1; Data in new indications expected in 2021 in anti-PD1 failed NSCLC, anti-PD1 failed CSCC and CSCC solid organ transplant recipient patients; further updates expected to be provided across all...
Replimune to Present at the 39th Annual J.P. Morgan Healthcare Conference
06. Januar 2021 08:00 ET
|
Replimune Group Inc
WOBURN, Mass., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today...
Replimune Announces First Patient Dosed with RP3 in a Phase 1 Clinical Trial in Patients with Advanced Solid Tumors
05. Januar 2021 08:00 ET
|
Replimune Group Inc
WOBURN, Mass., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform,...
Replimune to Participate at the SVB Leerink Oncology 1x1 Day
12. November 2020 08:00 ET
|
Replimune Group Inc
WOBURN, Mass., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Replimune Group Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today...
Replimune Announces Poster Presentations at the SITC 2020 Annual Meeting and a Presentation at the SITC 2020 Annual Meeting Virtual Press Conference
09. November 2020 08:00 ET
|
Replimune Group Inc
WOBURN, Mass., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Replimune Group Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform,...